Latest news

Adalvo announces the successful DCP approval for Ethinylestradiol/Drospirenone 0.03mg /3mg tablets.  Based on the reference brand Yasmin, Ethinylestradiol/Drospirenone has been developed in collaboration with one of our strategic partners. The INN is a...

Adalvo has successfully launched Dimethyl Fumarate (DMF) across various markets, serving over 20 partners on three continents. Dimethyl Fumarate 120mg and 240mg hard capsules have been developed based on the reference brand Tecfidera,...

Adalvo has successfully launched the first and only Pregabalin Extended-Release (ER) tablets in Europe. This differentiated product has been introduced in two major European markets, Germany and Spain, through partnerships...

Adalvo secures successful DCP approval for Mirabegron 50mg prolonged-release tablets.  Developed based on the reference brand Betmiga prolonged-release tablets, Mirabegron is indicated for the treatment of urgency, increased micturition frequency, and/or...

Adalvo successfully launched the first and only Desmopressin Orally Disintegrating Tablets (ODT) in Europe in March 2024.  Developed based on the reference brand Minirin Melt, Desmopressin ODT is indicated for the...

Adalvo announces the successful earlier-than-expected DCP approval for Empagliflozin 10mg and 25mg film-coated tablets.  Our product has been developed based on the reference brand Jardiance film-coated tablets, which are indicated for...

Adalvo announces the restart of the DCP procedure for Dapagliflozin Film-Coated Tablets, with an anticipated EU Marketing Authorisation approval date in October 2024.  Developed based on the reference brand Forxiga film-coated...

Adalvo announces the successful DCP submission for Empagliflozin/Metformin film-coated tablets, with an anticipated approval date in June 2025.  Developed based on the reference brand Synjardy film-coated tablets, Empagliflozin/Metformin is indicated for...

Adalvo announces the successful DCP approval for Apixaban Tablets.   Based on the reference brand Eliquis, Apixaban is indicated for the treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)....

Adalvo announces the addition of Voclosporin 7.9mg Soft Gel Capsules to its portfolio. Based on the reference brand Lupkynis, Voclosporin is indicated for treating adult patients with Lupus Nephritis (LN). Voclosporin represents the...

Adalvo announces the successful completion of the Pivotal BE study for Azacitidine 300mg film-coated tablets in adult patients with acute myeloid leukaemia (AML). Following the successful EU Pivotal BE study, Azacitidine...

Adalvo advances in the development of Fidaxomicin Film Coated Tablets 200mg, expecting dossier completion within the next six months. Following this, Adalvo intends to immediately file Fidaxomicin, having DCP slots already secured for...

Adalvo announces the addition of Olaparib Film Coated Tablets to its expanding oncology portfolio.  As a leading PARP inhibitor, Olaparib has received the most FDA approvals across four tumor types, underscoring...

Adalvo announces the successful launch of Rivaroxaban Film-Coated Tablets in the United Kingdom. Developed based on the reference brand Xarelto, Rivaroxaban is indicated for the prevention of atherothrombotic events in adult...

Adalvo has developed one of the broadest diabetes pipelines in the industry with an extensive range of therapeutic options. Our diverse portfolio includes small molecules and peptide-based treatments, encompassing both oral...

Adalvo and Gebro Pharma announce the successful launch of Pregabalin Prolonged Release Tablets in Spain, under the brand Dalingo®.  This product, indicated for treating Neuropathic Pain, is set to enhance patient adherence...

Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU. As a bioequivalent version of Victoza® pre-filled pen, indicated for the treatment...

Adalvo has completed the development of Semaglutide 1.34mg/ml pre-filled pen, a generic and bioequivalent version of Ozempic®, which is indicated for treating type II diabetes.   Having filed as the first company...

Adalvo announces the successful completion of the Pivotal BE study of Ambrisentan/Tadalafil Film-Coated Tablets 5mg/20mg under Fed and 10mg/40mg under Fasting conditions.   With the successful completion of our initial studies, we...

Adalvo is on target to file the Ruxolitinib Immediate Release (IR) Tablets dossier in Q4 2024. Filing upon dossier readiness, Adalvo aims to be among the first companies to launch this...

Adalvo announces the successful DCP approval for Dalbavancin 500mg Powder for concentrate for solution for infusion.  This niche antibiotic has been developed based on the reference brand Xydalba (EU) and is...